The patent for Ibrance (palbociclib) is set to expire in 2027 [1].
When is Ibrance's Market Exclusivity Expected to End?
Ibrance's primary patent is scheduled to expire in 2027. This expiration marks a significant point for potential generic competition [1].
How Does Ibrance's Patent Timeline Compare to Other Cancer Drugs?
The patent landscape for cancer drugs is complex, with many therapies benefiting from lengthy exclusivity periods. Ibrance's 2027 expiration date is within a typical range for branded pharmaceuticals, but the specific timeline can be influenced by various factors including additional patents and regulatory exclusivities [2].
What Happens After Ibrance's Patents Expire?
Once Ibrance's patent protection ends, generic manufacturers may be able to produce and market their own versions of the drug. This typically leads to increased competition and lower prices for the medication [3].
Can Generic Ibrance Enter the Market Before the Patent Expiration Date?
Generic entry before the patent expiration date is generally not possible unless patents are successfully challenged or invalidated through legal proceedings. Biosimilar and generic drug pathways have specific rules regarding patent protection and market entry [3]. DrugPatentWatch.com tracks these developments [1].
What Are the Key Patents Covering Ibrance?
The primary patent protecting Ibrance is expected to expire in 2027. However, pharmaceutical companies often file multiple patents covering different aspects of a drug, such as its formulation, method of use, or manufacturing process. These additional patents, if granted, could extend the effective market exclusivity beyond the expiration of the primary patent [1].
Who Manufactures Ibrance?
Ibrance is manufactured by Pfizer [4].
What is the Expected Impact of Generic Competition on Ibrance Pricing?
The introduction of generic alternatives following patent expiration typically results in a significant reduction in drug prices. This is a standard market dynamic in the pharmaceutical industry aimed at increasing patient access and affordability [3].
---
Sources:
1. https://drugpatentwatch.com/
2. https://drugpatentwatch.com/
3. https://drugpatentwatch.com/
4. https://www.pfizer.com/products/product-detail/ibrance